Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. Menzies D, Adjobimey M, Ruslami R, et al. Factors that influence treatment completion for latent tuberculosis infection. 2012 12:468.Įastment MC, McClintock AH, McKinney CM, et al. public health clinic: a prospective cohort study. Predictors of latent tuberculosis treatment initiation and completion at a U.S. Goswami ND, Gadkowski LB, Piedrahita C, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. TB Trials Consortium PREVENT TB Study Team. Sterling TR, Villarino ME, Borisov AS, et al. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. Latent TB infection treatment FAQs for clinicians. The BCG World Atlas: a database of global BCG vaccination policies and practices. QuantiFERON-TB Gold+ for the diagnosis of Mycobacterium tuberculosis infection. Underreading of the tuberculin skin test reaction.
Kendig EL, Kirkpatrick BV, Carter WH, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Lewinsohn DM, Leonard MK, LoBue PA, et al. Health care personnel (HCP) baseline individual TB risk assessment. health care personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. Tuberculosis screening, testing, and treatment of U.S.
Tuberculosis among foreign-born persons in the United States. WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025. Screening, diagnosis, and treatment of latent tuberculosis infection (LTBI) in primary care settings. Core curriculum on tuberculosis: what the clinician should know. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. ĭeutsch-Feldman M, Pratt RH, Price SF, et al. Ĭenters for Disease Control and Prevention. Consultation with a TB expert is necessary if there is suspicion or confirmation of drug-resistant TB. Treatment of drug-susceptible TB disease includes an eight-week intensive phase with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol), followed by a continuation phase lasting 18 weeks or more, with two drugs based on susceptibility testing results. Preferred treatment regimens for LTBI include isoniazid in combination with rifapentine or rifampin, or rifampin alone for a duration of three and four months, respectively. Both suspected and confirmed cases of LTBI and TB disease must be reported to local or state health departments. After a positive test result, chest radiography should be performed and, in patients with suspected pulmonary TB disease, sputum collected for diagnosis. Because the incidence of LTBI in health care professionals is similar to that of the general population, periodic retesting is not recommended. Preventive Services Task Force recommends testing individuals at increased risk of LTBI with an interferon-gamma release assay or tuberculin skin testing. Individuals with symptoms of TB disease warrant testing. Without treatment, LTBI will progress to active TB disease in approximately 5% to 10% of affected people. In the United States that same year, there were nearly 9,000 reported cases of TB disease and up to 13 million people were living with latent TB infection (LTBI), which is an asymptomatic, noncommunicable infection caused by Mycobacterium tuberculosis. Approximately 10 million people worldwide were infected with tuberculosis (TB) in 2019, resulting in 1.4 million deaths.